Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants

08.09.2005


A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.



In the phase II trial, researchers were attempting to determine if patients with multiple myeloma or non-Hodgkin’s lymphoma who received the drug AMD-3100 along with the standard drug G-CSF (granulocyte-colony stimulating factor) would have more stem cells available for transplantation.

AMD-3100 blocks a specific cellular receptor, triggering the movement of stem cells out of the bone marrow and into the circulating blood, boosting the supply of marrow stem cells available for transplantation. Stem cell transplantation entails collecting certain types of cells known as hematopoietic stem cells from patients who receive treatment with high-dose radiation and/or chemotherapy for cancers such as leukemias, lymphomas and multiple myeloma, all of which involve the blood and immune system. The cells, once returned to the body, help restore the blood-forming system within the bone marrow – and the body’s immune system, which is severely damaged if not destroyed by treatment.


Stem cell transplantation is considered "front-line therapy for multiple myeloma, or cancer of the bone marrow, and for high-risk leukemia and lymphoma patients," says Neal Flomenberg, M.D., professor of medicine and director of medical oncology at Jefferson Medical College of Thomas Jefferson University, who led the trial at Jefferson.

The researchers found that all of the 25 patients (10 patients with multiple myeloma and 15 patients with non-Hodgkin’s lymphoma) given the drug combination could move enough cells from the marrow to the bloodstream compared to only 64 percent of those who had G-CSF alone. They report their results September 1, 2005 in the journal Blood.

As a result, Dr. Flomenberg says, there were fewer stem cell collections necessary and more stem cells retrieved. The greater the number of available stem cells, the more likely transplantation will be successful. In some cases, this can mean the difference between a patient being able to receive a transplant or not. The drug has little toxicity.

"One of the most important results from the trial was that nine patients who would not have been able to mobilize stem cells to go to transplant with G-CSF alone could now mobilize them with the combination of G-CSF and AMD-3100," Dr. Flomenberg says.

In addition, some patients who received AMD-3100 needed fewer stem cell collections to get the necessary number of cells, making the overall process less taxing. Those who still required the same number of collections had a higher total of stem cells.

"It’s hoped that the drug combination will make white cell and platelet recovery quicker and allow patients who wouldn’t have otherwise been able to mobilize stem cells for transplant now be able to do so," he says. Without adequate numbers of stem cells for transplantation, patients may have a delayed recovery of their immune systems and be at greater risk of infection.

Most patients undergo standard chemotherapy for four to eight months before they have a stem cell transplant, he explains. Some patients won’t have a transplant until their disease relapses and treatment once again puts them back in remission. These treatments sometimes make subsequent stem cell collection difficult.

Approximately 25 percent to 35 percent of transplant patients – and perhaps as many as 65 percent – have trouble moving optimal numbers of stem cells from their bone marrow into the bloodstream using G-CSF. "Some patients with the standard approach don’t mobilize well, meaning more collections and often a poor or unusable cell product," he says.

Dr. Flomenberg believes that the drug combination will become a standard treatment for such cases involving stem cell transplantation. "The treatment has potential to alter the standard of practice," he says.

Researchers currently are conducting two phase III trials comparing G-CSF and placebo to G-CSF and AMD-3100 in 600 patients with either non-Hodgkin’s lymphoma or multiple myeloma, he notes. Jefferson is participating in both trials, in addition to another phase II trial with AMD-3100 alone.

The research is sponsored by AnorMED, Inc., a Vancouver, British Columbia-based drug development company. AnorMED’s efforts are aimed at the discovery and development of small molecule therapeutics to treat diseases including HIV, rheumatoid arthritis, asthma and cancer.

Steve Benowitz | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Life Sciences:

nachricht Cnidarians remotely control bacteria
21.09.2017 | Christian-Albrechts-Universität zu Kiel

nachricht Immune cells may heal bleeding brain after strokes
21.09.2017 | NIH/National Institute of Neurological Disorders and Stroke

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Comet or asteroid? Hubble discovers that a unique object is a binary

21.09.2017 | Physics and Astronomy

Cnidarians remotely control bacteria

21.09.2017 | Life Sciences

Monitoring the heart's mitochondria to predict cardiac arrest?

21.09.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>